iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/19668542/
Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:3:33-9.
Epub 2009 Jun 2.

Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany

Thomas Kaercher  1 , Patricia Buchholz, Friedemann Kimmich
Affiliations

Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany

Thomas Kaercher et al. Clin Ophthalmol. 2009.

Abstract

Objective: To evaluate the efficacy and tolerability of Optive, a new dry eye product containing sodium carboxymethylcellulose (0.5%) and glycerol (0.9%), in patients with keratoconjunctivitis sicca (KCS).

Methods: This was a non-interventional and observational study including patients with dry eye who required a change of medication or were naïve to dry eye treatment (N = 5,277). Disease severity, tear break-up time (TBUT), tolerability, and change in clinical symptoms were recorded at baseline and at final visit (2 to 4 weeks after first treatment).

Results: The severity of KCS was mild in 18.6%, moderate in 59.9%, and severe in 21.5% of patients based on physicians' assessment. TBUT was measured in 4,338 patients before switching to or initiating therapy with Optive and at final visit. Baseline measurement of mean TBUT was 7.7 +/- 3.9 seconds. This value increased to 10.0 +/- 4.7 seconds at final visit. Most patients (85.4%) reported improvement in local comfort. The majority (75.1%) of patients felt an improvement in symptoms after changing their treatment. Two percent of patients reported adverse events, and 0.4% were treatment-related.

Conclusions: Optive was well tolerated and improved the symptoms of dry eye after 2 to 4 weeks.

Keywords: Optive™; dry eye; glycerol; keratoconjunctivitis sicca; sodium carboxymethylcellulose.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in the clinical signs and symptoms at 2 to 4 weeks after switching to Optive.
Figure 2
Figure 2
Change in local comfort at 2 to 4 weeks after switching to Optive. The “improvement” category included patients with somewhat to major improvement.
Figure 3
Figure 3
Tear break-up time (TBUT) for all patients. Top panel illustrates the change in TBUT from baseline to final visit after switching to Optive across 7 time categories (≥0 to <4, ≥4 to <6, ≥6 to <8, ≥8 to <10, ≥10 to <12, ≥12 to <15, and ≥15 seconds). Bottom panel illustrates the mean TBUT ± standard deviation (seconds) from baseline to final visit across the categories of dry eye disease severity, to which patients were assigned at initial assessment. Asterisk indicates statistical significance (p < 0.001).
Figure 4
Figure 4
Patient satisfaction with the use of Optive. The results in the “satisfied” category showed here included patients who were somewhat satisfied to very satisfied.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007) Ocul Surf. 2007;5:75–92. - PubMed
    1. Schein OD, Muñoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723–728. - PubMed
    1. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264–1268. - PubMed
    1. Goto E, Yagi Y, Matsumoto Y, Tsubota K. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol. 2002;133:181–186. - PubMed
    1. Nichols KK. 2006. Patient-reported symptoms in dry eye disease. Ocul Surf. 2006;4:137–145. - PubMed

LinkOut - more resources